Navigation Links
ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)

MOUNTAIN VIEW, Calif., Sept. 21 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD).  CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials.  These data were presented today in a poster presentation entitled "CCR2 Antagonist CCX140-B in Phase 2 for Diabetes" in Stockholm, Sweden.  Data from an ongoing Phase II clinical trial in patients with type 2 diabetes mellitus is expected by the end of 2010 or early 2011.  

Results showed that daily treatment with CCX140 significantly improved fasting glucose and ameliorated insulin resistance (HOMA-IR) in obese, diabetic mice over a 28 day treatment period without a corresponding increase in MCP-1 (also called chemokine ligand 2 (CCL2)), the main ligand for CCR2.  Circulating adiponectin levels were significantly reduced in obese, diabetic mice and this was reversed when treated with CCX140.  The metabolic improvements also correlated with a significant reduction in adipose tissue inflammatory macrophage numbers. The preclinical studies were followed by Phase I clinical trials in 88 healthy human subjects.  These Phase I studies comprised single and multiple ascending dose placebo-controlled administration of CCX140 at doses ranging from 0.05 mg to 10 mg per day.  CCX140 was well tolerated in the Phase I trials with a favorable pharmacokinetic profile suitable for 5 to 10 mg once-daily oral treatment.  A Phase II clinical trial in 140 subjects with type 2 diabetes mellitus on stable doses of metformin was initiated earlier this year based on these encouraging preclinical and Phase I clinical results. The Phase II clinical trial is ongoing.  

"These very encouraging results to date support further evaluation of CCX140 in advanced clinical trials for the treatment of patients with type 2 diabetes," said Thomas J. Schall, President and Chief Executive Officer of ChemoCentryx.  "In addition to a high degree of target specificity and metabolic benefits, CCX140 is clearly differentiated from other marketed products with its added potential to treat the underlying mechanisms of type 2 diabetes and associated complications such as nephropathy and retinopathy.   The results of these trials continue to lead us to believe that CCX140 will be a meaningful and novel treatment option for patients who suffer from type 2 diabetes."

About Type 2 Diabetes and CCR2

Type 2 diabetes is a common metabolic disorder of high blood glucose associated with insulin resistance. It is differentiated from type 1 diabetes in which the primary defect is the inability of the pancreas to produce insulin. Patients with type 2 diabetes often require medication to maintain glucose homeostasis. The incidence of type 2 diabetes has reached epidemic proportions, associated in part with the rise in the incidence of weight gain and sedentary lifestyle. Despite available therapies, such as metformin, sulfonylureas, thiazolidinediones, incretin mimetics and other therapies, an unmet medical need for safe and convenient treatments persists.

For decades, the presence of systemic markers of inflammation has been known to increase with obesity. The adipose tissue has been shown to express multiple inflammatory cytokines, including TNF-a, IL-6, and MCP-1, the expression levels of which correlate with the degree of adiposity. Several of these mediators, including MCP-1 (also called chemokine ligand 2 (CCL2)), the main ligand for CCR2, have been shown to impair insulin-stimulated glucose uptake in adipose tissue, skeletal muscle and liver, providing a link between inflamed adipose tissue and insulin resistance.

CCX140 is chemically distinct from all other known antagonists of CCR2 and works by blocking the monocyte/macrophage infiltration that occurs during inflammation and thus is designed to provide selective treatment of the disease without compromising other immune functions.

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial.  Phase III clinical trials of Traficet-EN are expected to initiate in the fourth quarter 2010.  In addition, CCX025, also a CCR9 antagonist, has successfully completed a Phase I clinical program. Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; and CCX168, a C5aR antagonist, in Phase I clinical development. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. For more information, please refer to

Certain statements in this press release may constitute "forward-looking statements". These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy or actual results to differ materially from those expressed or implied. We do not intend, and undertake no obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Trovagene, Inc. ... diagnostics, today announced that Chief Executive Officer Antonius Schuh, ... the 27 th Annual Piper Jaffray Healthcare Conference. ... at the New York Palace Hotel in ... at 1:30 p.m. EST. Mr. Schuh will be available ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Today AVACEN Medical announced the issue of ... Thermal Energy Including Blood Viscosity Adjustment ". This patent shields the company,s AVACEN 100 dry heat ... Treatment Method. Photo - ... ... ...
(Date:11/25/2015)... 2015 Allergan plc (NYSE: AGN ... Therapeutics, a start-up  biotechnology company focused on the ... and funded by the F-Prime Biomedical Research Initiative ... an exclusive collaboration to support the discovery and ... (ASD) and Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology:
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... certified to offer their patients the many benefits of the revolutionary BIOLASE WaterLase ... sharp cutting and scraping tools traditionally used by a dentist in Gettysburg, ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... their Black Friday sale a week early, offering 40% off select bras and ... intimate apparel industry through both mobile fit technology and the latest fashion, quickly ...
(Date:11/24/2015)... ... ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, Dec. ... has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) falls under ... the device regulations. , Come up short in an inspection and the FDA can ...
(Date:11/24/2015)... ... November 24, 2015 , ... United Benefit Advisors (UBA), the ... Company as its newest Partner Firm. Based in Jefferson City, Missouri, their core ... advisor regardless of whether that client is a business, a family, or an ...
(Date:11/24/2015)... LINCOLN, R.I. (PRWEB) , ... November 24, 2015 , ... ... why Amica Insurance is sharing safety tips to help protect your family and vehicle. ... traffic crashes around the 2013 Thanksgiving holiday weekend. Amica is sharing the following safety ...
Breaking Medicine News(10 mins):